Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

HBP.TO Relative to the S&P 500

HBP.TO Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Helix BioPharma Corp. (TSE:HBP.TO) seasonal charts above shows that a Buy Date of August 10 and a Sell Date of November 11 has resulted in a geometric average return of 13.51% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 14 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 21.91% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development. It develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. The company has Tumor Defense Breakers (L-DOS47), and Tumor Attackers (CAR-T) product candidates in the pipeline.

To download HBP.TO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: HBP.TO